Advice
Marketing Authorisation Withdrawn
On 1 May, 2018, the marketing authorization for simprevir (Olysio) was withdrawn.
Medicine details
- Medicine name:
- simeprevir (Olysio)
- SMC ID:
- 988/14
- Indication:
- In combination with other medicinal products for the treatment of chronic hepatitis C in adult patients.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 13 October 2014
Additional notes
On 1 May 2018, the European Medicines Agency (EMA) published a statement regarding simprevir (Olysio). The manufacturer, Janssen have withdrawn the marketing authorisation.